TD Asset Management Inc Trims Stock Holdings in AstraZeneca PLC $AZN

by · The Cerbat Gem

TD Asset Management Inc reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 18.0% in the second quarter, Holdings Channel.com reports. The fund owned 908,339 shares of the company’s stock after selling 199,851 shares during the quarter. TD Asset Management Inc’s holdings in AstraZeneca were worth $63,475,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of AZN. Goldman Sachs Group Inc. boosted its stake in shares of AstraZeneca by 30.9% during the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock valued at $1,003,124,000 after purchasing an additional 3,224,251 shares during the period. Valeo Financial Advisors LLC lifted its holdings in AstraZeneca by 14,797.3% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock valued at $162,306,000 after buying an additional 2,307,047 shares in the last quarter. American Century Companies Inc. lifted its holdings in AstraZeneca by 406.9% during the 1st quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock valued at $148,517,000 after buying an additional 1,621,974 shares in the last quarter. Boston Partners grew its stake in AstraZeneca by 35.9% in the 1st quarter. Boston Partners now owns 5,036,645 shares of the company’s stock worth $368,712,000 after acquiring an additional 1,329,166 shares in the last quarter. Finally, Deutsche Bank AG grew its stake in AstraZeneca by 650.1% in the 1st quarter. Deutsche Bank AG now owns 1,234,847 shares of the company’s stock worth $90,761,000 after acquiring an additional 1,070,223 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.3%

NASDAQ AZN opened at $84.83 on Thursday. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $86.57. The company has a 50 day moving average price of $79.82 and a 200 day moving average price of $73.69. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The firm has a market cap of $263.09 billion, a PE ratio of 31.89, a price-to-earnings-growth ratio of 1.56 and a beta of 0.36.

AstraZeneca (NASDAQ:AZN – Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $14.46 billion during the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. AstraZeneca’s revenue was up 16.1% compared to the same quarter last year. During the same period last year, the firm earned $1.24 earnings per share. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were paid a $0.505 dividend. The ex-dividend date was Friday, August 8th. This represents a yield of 200.0%. AstraZeneca’s dividend payout ratio (DPR) is 37.97%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AZN. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research note on Wednesday, July 9th. Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Get Our Latest Analysis on AZN

AstraZeneca Company Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN – Free Report).